A 72-year-old man who had been taking rifampin daily for several months was concurrently administered warfa rin daily for ten weeks. During this period, the prothrombin time (FT) rose remarkably little as the dosage of warfarin was increased. With difficulty, satisfactory anticoagulation was achieved by giving warfarin 20 mg daily. On discontinuation of rifampin therapy, the FT increased significantly, and subsequent stabilization of the FT with in therapeutic range required treatment with warfarin 7.5 mg daily.
CASEREPORT
The patient, a 72-year-old man, was admitted to the West Tennessee Chest Hospital on April 14, 1974 with symptoms of congestive heart failure. In August, 1973 the patient was told he had pulmonary tuberculosis and was hospitalized for four months. His only medication since December, 1973 was rifampin 600 mg daily and ethambutol 1,000 mg daily. Prior chest x-ray films had shown borderline cardiomegaly, and he had labile hypertension during the earlier hospitalization. Examination showed blood pressure 110/60 mm Hg, pulse rate 116 per min, respiration rate 36 per min, and weight 52.4 kg. He was in mild respiratory distress and slightly confused. Other findings were a hepatojugular reflux, dullness and rÃ¢les in the right lower portion of the chest, pulsus altemans, and an S3 gallop. The liver was enlarged; chest x-ray films confirmed cardiomegaly and right pleural effusion. Mild pretibial edema was present; distal and radial pulses were absent. Electrocardiogram revealed sinus tachycardia and ab normal ST-T changes. Laboratory data included the follow ing: hematocrit, 39 percent; white blood cell count, 6,400/cu mm; serum sodium, 134 mEq/liter; potassium, 4.3 mEq/liter; chlorides, 106 mEq/liter; and bicarbonate, 14 mEq/L; blood urea nitrogen, 76 mg percent; creatmine, 3.6 mg percent; cal cium, 2.0 mEq/liter; phosphorus, 3.4 mEq/liter; total protein, 7.4 gm percent; albumin, 3.0 gm percent; and serum thyroxine, 4.7 percent.
The patient was initially treated for congestive heart fail ure with digitalis and diuretics and with heparin as an anticoagulant for suspected pulmonary emboli. There was difficulty in controlling the congestive heart failure shortly after admission to the hospital. His condition was worse on April 26 and pulmonary edema developed on May 2. Serum calcium levels were repeatedly 1.8-2.4 mEq/liter, and he was given vitamin D 50,000 units daily, after which the calcium levels increased to 4.4 mEq/liter. Since May 22 his cardiac classification has been class 3C, and the serum creatinine value decreased to 1.6 mg percent. Therapy with rifampin 600 mg daily and ethambutol 1,000 mg daily was continued from the first day of hospitalization. After initial anticoagulant treatment with heparin, the therapy was converted to warfarin. The patient's response to administration of warfarin is depicted in Figure 1 . In general, repeated increases in warfarin dosage resulted in only small increases in the PT as long as rifampin was being adminis tered. Only May 3, a PT of 30.8 seconds ( patient)/12.8 seconds ( control ) was reported. This response came 72 hours after a 35-mg dose of warfarin. The PT on May 13 was 26.9/13.4 (an increase of 10.1 seconds from the previous day); no obvious explanation for this increase could be determined. Beginning May 22, the dosage of warfarin was gradually increased, but the PT rose remarkably little until June 13 when it increased to 22.4/11.4. This relatively sudden rise was most probably due to the oral administration of quinidine 1 gm on June 10. Quinidine has been reported to enhance the action of warfarin.3-4 By June 19 the PT had decreased to 16.9/11.4, and by July 1, although the patient was receiving 20 mg warfarin daily, the PT was 23.9/12.1.
Administration of rifampin 600 mg daily was discontinued after the 8 AM dose on June 30, and isoniazid 300 mg daily was initiated; therapy with warfarin 20 mg daily and ethambutol 1,000 mg daily was continued. By July 5 the PT had risen only to 25.6/11.3, but on July 8 the PT was 37.8/11.6. Phytonadione 15 mg was given orally on July 8 and by the next day the PT had dropped to 18.1/11.9. Warfarin treat ment 15 mg daily was started on July 8, and in five days the PT was 36.9/12.9. Warfarin was not administered July 15 and 16. On July 16 a PT of 41.6/11.6 was reported, and by the following day the PT was 23.4/11.4. Liver function was checked and found to be within normal limits. Warfarin therapy 7.5 mg daily was begun on July 17 and was main tained because it provided adequate anticoagulation.
DISCUSSION
Michot et al1 describe the inhibition of the activity of acenocumarol, a coumarin anticoagulant, by rifampin. This study is possibly the primary basis for the state ments regarding the interaction potential of rifampin and orally administered anticoagulants made by VallSpinosa and Lester2 and by the pharmaceutical manu facturers of rifampin. Nitti et al5 suggest that rifampin may have an enzyme-inducing effect. The possibility that rifampin may increase the metabolic rate of orally administered anticoagulants is appealing as a possible mechanism for this interaction because the PT was not significantly increased for eight days after discontinua tion of rifampin. O'Reilly6 states that treatment with rifampin may enhance the excretion of warfarin. How ever, the mechanism for this interaction remains to be clearly defined.
While our patient was receiving rifampin, the PT rose little with increasing dosage of warfarin. However, after discontinuation of rifampin therapy, a significant in crease in warfarin activity was seen. When the patient was not receiving rifampin, satisfactory anticoagulation was achieved with administration of warfarin 7.5 mg daily.
